Scholarlink

<p>Alpha-glucosidase is a notable target in the treatment of postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). The present study showed that total phenol and flavonoid contents of <i>Artocarpus heterophyllus</i> leaves (AHL, 33 ± 0.26 &#xa0;µg GE/mg AHL&#xa0;and 15 ± 13.26&#xa0;&#xa0;µg QE/mg AHL) and AHL-MgONPs (20 ± 0.36 µg GE/mg AHL-MgONPs&#xa0;and 10 ± 12.8&#xa0;µg QE/mg AHL-MgONPs) were identified. UV–vis spectroscopy FTIR and XPS spectrum peak reduction were validated AHL-MgONPs synthesis whose amorphous nature and size was revealed through XRD and SEM. DLS study showed stable nature of AHL-MgONPs. AHL-MgONPs exhibited significant antioxidant (DPPH, ABTS, and FRAP) with IC<sub>50</sub> values 82.9 ± 4.39, 57 ± 3.26 and 51 ± 2.18&#xa0;µg/ml, respectively. Anti-inflammatory (IC<sub>50</sub> = 49.6 ± 2.24&#xa0;µg/ml) and antidiabetic activities [mammalian α-glucosidases (maltase, glucoamylase, sucrase, isomaltase) with IC<sub>50</sub> and Ki values, such as 304.6 ± 6.54, 368 ± 28.22, 209 ± 14, 204.9 ± 12.05, and 162, 162, 91, and 80&#xa0;µg/ml, respectively. Finally, AHL-MgONPs enhanced&#xa0;glucose uptake assay (IC<sub>50</sub> = 287.7 ± 43.25&#xa0;µg/ml)] in dose-dependent manner and explored mixed types of inhibition on mammalian alpha-glucosidases than core nanoparticles. These findings lend credence to use of AHL-MgONPs for the treatment of inflammation, oxidative stress, and T2DM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis of Magnesium Oxide Nanoparticles Using Artocarpus heterophyllus Leaves Extract and Their In Vitro Antioxidant, Anti-inflammatory, and Antidiabetic Properties

  • 期刊论文

  • 发表日期：

    2025年5月22日

查看全文
  • Parveen Abdulhaniff,
  • Chitra Loganathan,
  • Penislusshiyan Sakayanathan,
  • Palvannan Thayumanavan

摘要

Alpha-glucosidase is a notable target in the treatment of postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). The present study showed that total phenol and flavonoid contents of Artocarpus heterophyllus leaves (AHL, 33 ± 0.26  µg GE/mg AHL and 15 ± 13.26  µg QE/mg AHL) and AHL-MgONPs (20 ± 0.36 µg GE/mg AHL-MgONPs and 10 ± 12.8 µg QE/mg AHL-MgONPs) were identified. UV–vis spectroscopy FTIR and XPS spectrum peak reduction were validated AHL-MgONPs synthesis whose amorphous nature and size was revealed through XRD and SEM. DLS study showed stable nature of AHL-MgONPs. AHL-MgONPs exhibited significant antioxidant (DPPH, ABTS, and FRAP) with IC50 values 82.9 ± 4.39, 57 ± 3.26 and 51 ± 2.18 µg/ml, respectively. Anti-inflammatory (IC50 = 49.6 ± 2.24 µg/ml) and antidiabetic activities [mammalian α-glucosidases (maltase, glucoamylase, sucrase, isomaltase) with IC50 and Ki values, such as 304.6 ± 6.54, 368 ± 28.22, 209 ± 14, 204.9 ± 12.05, and 162, 162, 91, and 80 µg/ml, respectively. Finally, AHL-MgONPs enhanced glucose uptake assay (IC50 = 287.7 ± 43.25 µg/ml)] in dose-dependent manner and explored mixed types of inhibition on mammalian alpha-glucosidases than core nanoparticles. These findings lend credence to use of AHL-MgONPs for the treatment of inflammation, oxidative stress, and T2DM.